Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Ingolia, Peter Meldrum, Alex Mackenzie

Premium

Thomas Ingolia has become the new CEO of Myriad Proteomics, based in Salt Lake City, replacing acting CEO Peter Meldrum. He started his new appointment this week. Most recently, Ingolia was working as a consultant for biopharma. Prior to that, he was president of Microbia of Cambridge, Mass. Before that, he held positions at Ontogeny, based in Cambridge, which subsequently became Curis. He also served in various positions at Eli Lilly. Ingolia holds a PhD in biochemistry from the University of California, Berkeley and an MBA from Indiana University.

 

Alex Mackenzie has become vice president of research for Genome Canada, effective July 1. He is currently director at the Children’s Hospital of Eastern Ontario’s Research Institute in Ottawa and professor of the faculty of medicine at the University of Ottawa.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.